Long-acting β2-agonists (LABA) in chronic obstructive pulmonary disease: efficacy and safety
A Rossi, S Khirani, M Cazzola - International journal of chronic …, 2008 - Taylor & Francis
COPD is characterized by progressive airflow obstruction which does not fully reverse to
inhaled or oral pharmacotherapy. The management of patients with COPD has taken a …
inhaled or oral pharmacotherapy. The management of patients with COPD has taken a …
[PDF][PDF] Long-acting β
A Rossi - International Journal of COPD, 2008 - pdfs.semanticscholar.org
COPD is characterized by progressive airflow obstruction which does not fully reverse to
inhaled or oral pharmacotherapy. The management of patients with COPD has taken a …
inhaled or oral pharmacotherapy. The management of patients with COPD has taken a …
[HTML][HTML] Long-acting β2-agonists (LABA) in chronic obstructive pulmonary disease: efficacy and safety
A Rossi, S Khirani, M Cazzola - International Journal of Chronic …, 2008 - ncbi.nlm.nih.gov
COPD is characterized by progressive airflow obstruction which does not fully reverse to
inhaled or oral pharmacotherapy. The management of patients with COPD has taken a …
inhaled or oral pharmacotherapy. The management of patients with COPD has taken a …
Long-acting beta2-agonists (LABA) in chronic obstructive pulmonary disease: efficacy and safety
A Rossi, S Khirani, M Cazzola - International journal of …, 2008 - pubmed.ncbi.nlm.nih.gov
COPD is characterized by progressive airflow obstruction which does not fully reverse to
inhaled or oral pharmacotherapy. The management of patients with COPD has taken a …
inhaled or oral pharmacotherapy. The management of patients with COPD has taken a …
Long-acting beta2-agonists (LABA) in chronic obstructive pulmonary disease: efficacy and safety.
A Rossi, S Khirani, M Cazzola - International Journal of Chronic …, 2008 - europepmc.org
COPD is characterized by progressive airflow obstruction which does not fully reverse to
inhaled or oral pharmacotherapy. The management of patients with COPD has taken a …
inhaled or oral pharmacotherapy. The management of patients with COPD has taken a …
[PDF][PDF] Long-acting β
A Rossi - International Journal of COPD, 2008 - researchgate.net
COPD is characterized by progressive airflow obstruction which does not fully reverse to
inhaled or oral pharmacotherapy. The management of patients with COPD has taken a …
inhaled or oral pharmacotherapy. The management of patients with COPD has taken a …
[PDF][PDF] Long-acting β
A Rossi - International Journal of COPD, 2008 - Citeseer
COPD is characterized by progressive airflow obstruction which does not fully reverse to
inhaled or oral pharmacotherapy. The management of patients with COPD has taken a …
inhaled or oral pharmacotherapy. The management of patients with COPD has taken a …
[PDF][PDF] Long-acting β
A Rossi - International Journal of COPD, 2008 - scienceopen.com
COPD is characterized by progressive airflow obstruction which does not fully reverse to
inhaled or oral pharmacotherapy. The management of patients with COPD has taken a …
inhaled or oral pharmacotherapy. The management of patients with COPD has taken a …
Long-acting β2-agonists (LABA) in chronic obstructive pulmonary disease: efficacy and safety
A Rossi, S Khirani, M Cazzola - International Journal of Chronic …, 2008 - dovepress.com
COPD is characterized by progressive airflow obstruction which does not fully reverse to
inhaled or oral pharmacotherapy. The management of patients with COPD has taken a …
inhaled or oral pharmacotherapy. The management of patients with COPD has taken a …
Long-acting beta2-agonists (LABA) in chronic obstructive pulmonary disease: efficacy and safety.
A Rossi, S Khirani, M Cazzola - International Journal of Chronic …, 2008 - europepmc.org
COPD is characterized by progressive airflow obstruction which does not fully reverse to
inhaled or oral pharmacotherapy. The management of patients with COPD has taken a …
inhaled or oral pharmacotherapy. The management of patients with COPD has taken a …